A recent study suggests that people who come off new weight-loss injections like Mounjaro or Wegovy tend to recover shed pounds much more quickly than those who halt traditional diet and exercise plans.
Findings released in a prominent health publication points out that while overweight people can lose substantial amounts of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month after stopping.
"People buying such medications should be informed of the risk of rapid weight regain when the treatment concludes," stated expert Dr. Susan Jebb.
That rate of regain implies a return to starting mass in about one and a half years.
Analyzing Treatments
The analysis, which reviewed 37 of trials involving over 9,000 of participants, compared the effects of the injectable medications with other pills.
The team point out that people who shed pounds through diet and exercise usually experience a more gradual weight regain—around 100 grams monthly—once they finish.
Understanding the Rapid Rebound
Doctors propose the way of the drugs explains the accelerated rebound.
The injections copy a body's own chemical called GLP-1, which moderates hunger.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production may cause the system to generate a reduced amount of its endogenous hormone, and could reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this hormone supplement results in appetite is no longer kept in check, making binge eating far more likely."
An Ongoing Disease?
The NHS suggest the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians argue that, due to the significant potential of relapse, the therapy might need to be ongoing.
This opinion is echoed by pharmaceutical companies, who note that the findings "highlight the chronic nature of excess weight," comparing it to managing diseases like hypertension.
User Testimonies
Individuals who have come off the medication report a powerful return of hunger.
"It was like a switch that goes on and I was suddenly extremely hungry," said a patient.
The struggle is compounded if patients have not established permanent lifestyle or habit modifications during therapy.
Significant Adoption
Figures show that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is higher among women than men.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
In conclusion, experts stress that while the jabs are potent agents for weight loss, they are not a permanent solution and long-term success hinges on ongoing lifestyle support.
